Arbutus Biopharma Corporation
Arbutus Biopharma Corporation (ABUS) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · ABUS · as of Jun 9, 2026
Key Statistics
Explore Arbutus Biopharma Corporation Data
abus stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 10 · Buy rate: 80.0%
The ABUS analyst consensus is Buy, based on ratings from 10 Wall Street analysts over the past 3 months. The average 12-month price target is $8.50, representing +100.47% upside from the current price of $4.24.
Competitors & Peers
abus competitorsABUS
BCAX
EYPT
GHRS
KURA
NBTXStock Performance
Full HistoryAbout Arbutus Biopharma Corporation
Arbutus Biopharma Corporation a biopharmaceutical company operating in the United States, focuses on the discovery and development of novel therapies for chronic Hepatitis B virus (HBV) infection, SA…
what is arbutus biopharma corporation · abus stock overview · arbutus biopharma corporation company profile · who is arbutus biopharma corporation ceo · abus NASDAQ · arbutus biopharma corporation headquarters · arbutus biopharma corporation business segments
About Stock Overview & Key Data
Arbutus Biopharma Corporation (ABUS) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Jul 26, 2007. As of the latest trading session, ABUS stock price is $4.24, with a market capitalization of $837.6M. The stock has returned +20.80% over the past 12 months and -11.85% year-to-date.
According to 10 Wall Street analysts, the consensus rating for Arbutus Biopharma Corporation stock is Buy, with an average 12-month price target of $8.50. In fiscal year 2025, Arbutus Biopharma Corporation reported revenue of $14.1M and net income of -$33.5M. For detailed data — including Arbutus Biopharma Corporation revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, Arbutus Biopharma Corporation (ABUS) stock price is $4.24. The stock is traded on NASDAQ under the ticker symbol ABUS. The 52-week range is $3.04 – $5.10.